[Pharmacokinetic and clinical consequences of the genetic polymorphism of oxidation].
Bufuralol is a beta-adrenoceptor blocking drug whose metabolism is under the same genetic control as debrisoquine. Bufuralol appears to be a sensitive tool for characterization of this pharmacogenetic variation. After test drug absorption, one single blood collection allows separation between extensive and poor metabolizers. In Switzerland, the poor metabolizer status has a prevalence of 8%. In poor metabolizers bufuralol plasma concentrations are very high, an observation of interest when considering the occurrence of side effects of the drug. In addition to disease-induced variability in drug response, oxidation polymorphism is a major source of interindividual variations in drug effect. As the metabolism of numerous drugs is affected by this pharmacogenetic variation, the question arises whether systematic screening should not be considered.
D000319:Adrenergic beta-Antagonists / Q000378:metabolism*; D000328:Adult; D000483:Alleles; D002851:Chromatography, High Pressure Liquid; D003647:Debrisoquin / Q000378:metabolism; D004983:Ethanolamines / Q000378:metabolism*; D006801:Humans; D006900:Hydroxylation; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic
D000319:Adrenergic beta-Antagonists; D004983:Ethanolamines; C010831:bufuralol; D003647:Debrisoquin
Conséquences pharmacocinétiques et cliniques du polymorphisme génétique de l'oxydation.